143 related articles for article (PubMed ID: 30958600)
1. JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Liu K; Zhou Z; Gao H; Yang F; Qian Y; Jin H; Guo Y; Liu Y; Li H; Zhang C; Guo J; Wan Y; Chen R
Cell Biol Int; 2019 Jun; 43(6):642-650. PubMed ID: 30958600
[TBL] [Abstract][Full Text] [Related]
2. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
Tian Y; Wang X; Zhao S; Liao X; Younis MR; Wang S; Zhang C; Lu G
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46626-46636. PubMed ID: 31751121
[TBL] [Abstract][Full Text] [Related]
3. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
Zhu H; Bengsch F; Svoronos N; Rutkowski MR; Bitler BG; Allegrezza MJ; Yokoyama Y; Kossenkov AV; Bradner JE; Conejo-Garcia JR; Zhang R
Cell Rep; 2016 Sep; 16(11):2829-2837. PubMed ID: 27626654
[TBL] [Abstract][Full Text] [Related]
4. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
5. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
[TBL] [Abstract][Full Text] [Related]
6. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
7. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
[TBL] [Abstract][Full Text] [Related]
8. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
[TBL] [Abstract][Full Text] [Related]
10. Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Zhao L; Li P; Zhao L; Wang M; Tong D; Meng Z; Zhang Q; Li Q; Zhang F
J Cell Biochem; 2020 Feb; 121(2):1855-1869. PubMed ID: 31633227
[TBL] [Abstract][Full Text] [Related]
11. Co-inhibition of BET proteins and PD-L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD-L1 expressions.
Wang W; Tan J
J Oral Pathol Med; 2019 Oct; 48(9):817-825. PubMed ID: 31177574
[TBL] [Abstract][Full Text] [Related]
12. BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response.
Andrieu GP; Shafran JS; Smith CL; Belkina AC; Casey AN; Jafari N; Denis GV
Cancer Lett; 2019 Nov; 465():45-58. PubMed ID: 31473251
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
[TBL] [Abstract][Full Text] [Related]
15. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
Hara T; Miyake H; Hinata N; Fujisawa M
Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
[TBL] [Abstract][Full Text] [Related]
17. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
18. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
19. Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration.
Russell JO; Ko S; Saggi HS; Singh S; Poddar M; Shin D; Monga SP
Am J Pathol; 2018 Jun; 188(6):1389-1405. PubMed ID: 29545201
[TBL] [Abstract][Full Text] [Related]
20. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]